Influenza Update

February 7, 2017
Overview

• Update on influenza-like-illness (ILI)
• Update on IHS influenza vaccine coverage
• Healthcare Personnel mid-season influenza vaccine coverage
• Update from the IHS National Supply Service Center
U.S. Influenza Activity

- ILI activity has been above the national baseline of 2.2% for the last 7 weeks
- Most activity so far has been caused by influenza A, H3N2 strain
- Circulating strains appear to be well matched to those in the 2016-2017 vaccine
- To date, there have been 15 influenza-associated pediatric deaths in the United States
  - Seven deaths were reported in week 4
FluView
A Weekly Influenza Surveillance Report Prepared by the Influenza Division

Percentage of Visits for Influenza-like Illness (ILI) Reported by the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet), Weekly National Summary, 2016-2017 and Selected Previous Seasons
Weekly Influenza Activity Estimates Reported by State & Territorial Epidemiologists*
Week ending January 28, 2017 - Week 4

* This map indicates geographic spread & does not measure the severity of influenza activity.
Pneumonia and Influenza Mortality from the National Center for Health Statistics Mortality Surveillance System

Data through the week ending January 7, 2017, as of February 2, 2017
U.S. Influenza Vaccine Supply

- Influenza vaccine supply:
  - Projected: 157 million - 168 million doses

- Distributed doses as of Jan. 27th, 2017
  - 145 million doses
IHS Influenza Awareness System as of 01/28/2017 (Week 4)

- The proportion of ILI visits across IHS is 2.2%, above the IHS ILI baseline of 1.77%
  - This is the 6th week that ILI visits have been elevated

- The majority of IHS regions are reporting elevated ILI activity

- ~310,000 doses of influenza vaccine have been administered in IHS

- Weekly IIAS reports available on the IHS Flu Website
  - www.ihs.gov/flu
IHS ILI Activity as of 01/28/2017
% of outpatient visits for influenza-like-illness (ILI)
All IHS Areas
Influenza-Like Illness (ILI) for All Surveillance Years
Percentage of Visits for ILI per week
01/04/09 to 01/28/2017

Week Number

Percentage ILI

0 1 2 3 4 5 6 7 8 9
Week 04

IHS Influenza Vaccine Coverage
# Influenza Vaccination Coverage by Age Group*

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Active Clinical Population**</th>
<th>Seasonal Flu Vaccine (At Least 1 Dose)***</th>
<th>% Seasonal Flu (At Least 1 Dose)</th>
<th>Seasonal Flu Vaccine (At Least 2 Doses)</th>
<th>% Seasonal Flu (At Least 2 Doses)</th>
<th>Total #Doses Administered****</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 - 5 months</td>
<td>4,644</td>
<td>44</td>
<td>0.9</td>
<td>0</td>
<td>0.0</td>
<td>45</td>
</tr>
<tr>
<td>6 - 23 months</td>
<td>22,203</td>
<td>11,555</td>
<td>52.0</td>
<td>2,649</td>
<td>11.9</td>
<td>14,282</td>
</tr>
<tr>
<td>2 - 4 years</td>
<td>54,360</td>
<td>15,060</td>
<td>27.7</td>
<td>400</td>
<td>0.7</td>
<td>15,569</td>
</tr>
<tr>
<td>5 - 17 years</td>
<td>204,208</td>
<td>62,293</td>
<td>30.5</td>
<td>418</td>
<td>0.2</td>
<td>63,157</td>
</tr>
<tr>
<td>18 - 49 years</td>
<td>415,749</td>
<td>101,181</td>
<td>24.3</td>
<td>563</td>
<td>0.1</td>
<td>102,617</td>
</tr>
<tr>
<td>50 - 64 years</td>
<td>173,443</td>
<td>67,121</td>
<td>38.7</td>
<td>414</td>
<td>0.2</td>
<td>68,174</td>
</tr>
<tr>
<td>65 + years</td>
<td>99,017</td>
<td>46,135</td>
<td>46.6</td>
<td>350</td>
<td>0.4</td>
<td>46,971</td>
</tr>
<tr>
<td>Children (6 months-17 years)</td>
<td>280,771</td>
<td>88,908</td>
<td>31.7</td>
<td>3,467</td>
<td>1.2</td>
<td>93,008</td>
</tr>
<tr>
<td>Adults (18 + years)</td>
<td>688,209</td>
<td>214,437</td>
<td>31.2</td>
<td>1,327</td>
<td>0.2</td>
<td>217,762</td>
</tr>
<tr>
<td>All (6 months +)</td>
<td>968,980</td>
<td>303,345</td>
<td>31.3</td>
<td>4,794</td>
<td>0.5</td>
<td>310,770</td>
</tr>
</tbody>
</table>
Influenza Vaccine Coverage as of 01/28/2017

- Adults (18 + years)
- All (6 months +)
- Children (6 months-17 years)
Influenza Vaccine Coverage
Week 04
2015-16 vs. 2016-2017
# Influenza Vaccine Doses Administered by Influenza Vaccine Type*

<table>
<thead>
<tr>
<th>Area</th>
<th>INACTIVE CVX CODES*</th>
<th>CVX 88 FLU-NOS**</th>
<th>CVX 111 FLU-LAIV3</th>
<th>CVX 135 FLU-HIGH</th>
<th>CVX 140 FLU-IIV3</th>
<th>CVX 141 FLU-DERMAL</th>
<th>CVX 144 FLU-IIV4</th>
<th>CVX 149 FLU-LAIV4</th>
<th>CVX 150 FLU-IIV4pf</th>
<th>CVX 153 FLU-ccIIV3</th>
<th>CVX 155 FLU-RIV3</th>
<th>CVX 158 IIV4</th>
<th>CVX 161 IIV4pf -ped</th>
<th>CVX 166</th>
<th>Proc 99.52 Vac Inf</th>
<th>ICD-9 V04.81 Vac Inf</th>
<th>CPT Billing Codes+</th>
<th>Cumulative # of Doses Seasonal Flu</th>
</tr>
</thead>
<tbody>
<tr>
<td>AKA</td>
<td>4</td>
<td>282</td>
<td>0</td>
<td>442</td>
<td>40</td>
<td>578</td>
<td>1</td>
<td>0</td>
<td>5844</td>
<td>1</td>
<td>2</td>
<td>3587</td>
<td>501</td>
<td>21</td>
<td>0</td>
<td>0</td>
<td>69</td>
<td>11372</td>
</tr>
<tr>
<td>ALB</td>
<td>1</td>
<td>195</td>
<td>0</td>
<td>1288</td>
<td>589</td>
<td>10305</td>
<td>1</td>
<td>0</td>
<td>4795</td>
<td>0</td>
<td>6</td>
<td>2050</td>
<td>703</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>89</td>
<td>20023</td>
</tr>
<tr>
<td>BEM</td>
<td>281</td>
<td>113</td>
<td>0</td>
<td>434</td>
<td>27</td>
<td>2765</td>
<td>0</td>
<td>1</td>
<td>3886</td>
<td>5</td>
<td>4</td>
<td>3355</td>
<td>331</td>
<td>46</td>
<td>0</td>
<td>2</td>
<td>256</td>
<td>11506</td>
</tr>
<tr>
<td>BIL</td>
<td>5</td>
<td>259</td>
<td>0</td>
<td>996</td>
<td>13</td>
<td>2250</td>
<td>0</td>
<td>0</td>
<td>10972</td>
<td>0</td>
<td>1</td>
<td>1696</td>
<td>986</td>
<td>157</td>
<td>0</td>
<td>0</td>
<td>124</td>
<td>17459</td>
</tr>
<tr>
<td>CAO</td>
<td>17</td>
<td>206</td>
<td>0</td>
<td>1383</td>
<td>29</td>
<td>2868</td>
<td>1</td>
<td>7</td>
<td>8262</td>
<td>0</td>
<td>2</td>
<td>5313</td>
<td>1544</td>
<td>59</td>
<td>0</td>
<td>2</td>
<td>125</td>
<td>19818</td>
</tr>
<tr>
<td>GPA</td>
<td>3</td>
<td>464</td>
<td>0</td>
<td>1054</td>
<td>149</td>
<td>12511</td>
<td>0</td>
<td>0</td>
<td>12459</td>
<td>12</td>
<td>26</td>
<td>5488</td>
<td>1159</td>
<td>9</td>
<td>0</td>
<td>0</td>
<td>100</td>
<td>33434</td>
</tr>
<tr>
<td>NSA</td>
<td>221</td>
<td>358</td>
<td>0</td>
<td>354</td>
<td>136</td>
<td>5621</td>
<td>235</td>
<td>0</td>
<td>4092</td>
<td>4</td>
<td>20</td>
<td>355</td>
<td>167</td>
<td>334</td>
<td>0</td>
<td>0</td>
<td>127</td>
<td>12024</td>
</tr>
<tr>
<td>NAV</td>
<td>28</td>
<td>371</td>
<td>1</td>
<td>1795</td>
<td>26</td>
<td>10009</td>
<td>9</td>
<td>0</td>
<td>12882</td>
<td>1</td>
<td>1</td>
<td>42781</td>
<td>2681</td>
<td>1078</td>
<td>0</td>
<td>0</td>
<td>200</td>
<td>71863</td>
</tr>
<tr>
<td>OKC</td>
<td>263</td>
<td>2389</td>
<td>0</td>
<td>2438</td>
<td>13</td>
<td>28842</td>
<td>7</td>
<td>1</td>
<td>9441</td>
<td>17</td>
<td>1</td>
<td>2791</td>
<td>1507</td>
<td>542</td>
<td>0</td>
<td>0</td>
<td>221</td>
<td>48473</td>
</tr>
<tr>
<td>PHX</td>
<td>3</td>
<td>535</td>
<td>0</td>
<td>1432</td>
<td>96</td>
<td>10432</td>
<td>20</td>
<td>0</td>
<td>21145</td>
<td>0</td>
<td>20</td>
<td>633</td>
<td>2447</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>228</td>
<td>36992</td>
</tr>
<tr>
<td>POR</td>
<td>10</td>
<td>430</td>
<td>1</td>
<td>778</td>
<td>1257</td>
<td>8174</td>
<td>12</td>
<td>1</td>
<td>5240</td>
<td>29</td>
<td>22</td>
<td>3473</td>
<td>389</td>
<td>1226</td>
<td>0</td>
<td>0</td>
<td>856</td>
<td>21898</td>
</tr>
<tr>
<td>TUC</td>
<td>0</td>
<td>56</td>
<td>0</td>
<td>32</td>
<td>28</td>
<td>8</td>
<td>0</td>
<td>0</td>
<td>6397</td>
<td>1</td>
<td>0</td>
<td>38</td>
<td>469</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>38</td>
<td>7067</td>
</tr>
<tr>
<td>HQ</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>311931</td>
</tr>
</tbody>
</table>

* Inactive CVX Codes 15 (FLU-TIVhx), 16 (FLU-WHOLE), 123 (FLU-H5N1), and 151 (FLU-NasNOS) should not be used to document flu vaccines given this flu season. Doses are NOT deduplicated.

** CVX Code 88 (FLU-NOS) should only be used to document flu vaccines given elsewhere when flu vaccine type is unknown.

+ CPT Flu codes include: 90654-90662, 90672-90673, 90685-90686, 90724, G0008, G8108.

^ ICD9 codes V04.8 and V06.6 are not displayed on this report and are not used in any of the influenza vaccine coverage calculations.
IHS Healthcare Personnel Influenza vaccine coverage
All Facilities
As of Dec. 31, 2016
IHS Healthcare Personnel Influenza vaccine coverage

IHS vs. Tribal

As of Dec. 31, 2016

- IHS: 84.3% (2015-2016) vs. 89.9% (2016-2017)
- Tribal: 68.6% (2015-2016) vs. 68.6% (2016-2017)
Summary

- Influenza activity continues to increase across the country
- Seasonal influenza vaccine appears to be well matched to circulating strains
- It's not too late to get vaccinated
  - Less than 1/3 of the IHS patient population has received an influenza vaccine
2016-17 Seasonal Influenza Vaccine and Antiviral Procurement

IHS National Supply Service Center
Pharmacy Support Branch
James J. Cummings, PharmD
James.Cummings@ihs.gov
<table>
<thead>
<tr>
<th>Product Name</th>
<th>Dosage Form</th>
<th>NDC</th>
<th>Price/dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Afluria®</td>
<td><strong>Multi-Dose Vial (MDV)</strong> -10 doses/vial Peds/Adult (9 years &amp; older)</td>
<td>33332-0116-10</td>
<td><strong>$5.49</strong></td>
</tr>
<tr>
<td>Fluzone®</td>
<td></td>
<td></td>
<td>49281-0516-25</td>
</tr>
<tr>
<td>Fluarix®</td>
<td></td>
<td></td>
<td>58160-0905-52</td>
</tr>
<tr>
<td>Fluzone® HD</td>
<td></td>
<td></td>
<td>49281-0399-65</td>
</tr>
<tr>
<td>Fluzone® ‡ Intradermal</td>
<td></td>
<td></td>
<td>49281-0710-40</td>
</tr>
<tr>
<td>Flumist® ‡ Intranasal</td>
<td></td>
<td></td>
<td>Did not offer</td>
</tr>
<tr>
<td>Flublok® ‡</td>
<td></td>
<td></td>
<td>42874-0016-10</td>
</tr>
</tbody>
</table>

# Vaccine is supplemental to the four contract vaccines and IHS receiving FSS pricing
Flu Vaccine Ordering
Post-Solicitation

• Contact “Gabe” Wyatt  aaron.wyatt@ihs.gov
  • He will forward a Flu 413 Form for ordering

• Submit Seasonal Flu Form 413 to NSSC
  • NSSC may have stock of additional contract vaccine
    ▪ If not NSSC will contact manufacturers to obtain and if authorized, will purchase additional vaccine
    If contract vaccine not available NSSC will contact additional vendors to find best price

• Occasionally, FSS priced vaccine available through McKesson but no guarantees
Antiviral Ordering & Procurement

• **Tamiflu® 75mg Capsules** may purchase from NSSC at substantially reduced prices by contacting “Gabe” Wyatt (Aaron.Wyatt@ihs.gov) and he will forward a 413 form

• Complete 413 and fax to “Gabe” (405) 951-6054 or e-mail

• Other dosage forms & strengths available thru McKesson

• Relenza® available thru McKesson Connect
Influenza Antiviral

• Tamiflu® Capsules, 75mg, BT/10 priced at $19.24 per bottle – Expires April 2017 (part of the Shelf Life Extension Program (SLEP) for on hand Please contact NSSC for purchasing)

NSSC can ship overnight delivery if needed the next day. Typically, we ship 2-3 day ground.